Marvel Biosciences Corp
XTSX:MRVL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Marvel Biosciences Corp
XTSX:MRVL
|
CA |
|
H
|
Haryana Capfin Ltd
BSE:532855
|
IN |
|
G
|
Giant Group Ltd
OTC:GGLT
|
US |
|
Marston's PLC
LSE:MARS
|
UK |
|
M
|
Metrofile Holdings Ltd
JSE:MFL
|
ZA |
Marvel Biosciences Corp
Marvel Biosciences Corp. operates as a biotechnology company that utilizes a drug redevelopment approach to drug development. The company is headquartered in Calgary, Alberta. The company went IPO on 2019-02-28. The firm is focused on the discovery of new chemical entities that inhibit the A2a adenosine receptor. The firm has developed several new chemical entities, using synthetic chemical derivatives of known drugs, that inhibit the A2a adenosine receptor with application to neurological diseases, including depression and anxiety, Alzheimer’s, attention deficit hyperactivity disorder (ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The firm is focused on the development of its lead molecule, MB-204 (Target 1b), which is in Phase I clinical trials. Its wholly owned subsidiary is Marvel Biotechnology Inc.
Marvel Biosciences Corp. operates as a biotechnology company that utilizes a drug redevelopment approach to drug development. The company is headquartered in Calgary, Alberta. The company went IPO on 2019-02-28. The firm is focused on the discovery of new chemical entities that inhibit the A2a adenosine receptor. The firm has developed several new chemical entities, using synthetic chemical derivatives of known drugs, that inhibit the A2a adenosine receptor with application to neurological diseases, including depression and anxiety, Alzheimer’s, attention deficit hyperactivity disorder (ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. The firm is focused on the development of its lead molecule, MB-204 (Target 1b), which is in Phase I clinical trials. Its wholly owned subsidiary is Marvel Biotechnology Inc.
